Sauvé Frédéric, Paradis Manon, Refsal Kent R, Moreau Maxim, Beauchamp Guy, Dupuis Jacques
Département de sciences cliniques, Faculté de médecine vétérinaire, Université de Montréal, C.P. 5000, Saint-Hyacinthe, Québec J2S 7C6.
Can Vet J. 2003 Jun;44(6):474-9.
The purpose of this study was to evaluate the effect of the administration of meloxicam; carprofen; and a slow-acting disease modifying osteoarthritis agent, that contains chondroitin sulfate, purified glucosamine, and manganese ascorbate (CS-G-M), on thyroid function in dogs. Forty-six healthy (except for osteoarthritis) euthyroid dogs were blindly assigned to 3 treatment groups: meloxicam, carprofen, and CS-G-M. Each group received the recommended dose of the drug for 60 days. Sixteen other osteoarthritic euthyroid dogs, which received a placebo, were used as a control group to validate the study. For all groups, blood samples were collected on days 0, 30, and 60 to evaluate the serum total and free thyroxine, and endogenous thyrotropin concentrations. There were no significant differences among the treatment groups at each time or within each group over a 60-day period for all parameters. Moreover, none of these values were within the hypothyroid range. Based on the results of this study, the administration of meloxicam, carprofen, and CS-G-M did not affect canine thyroid function evaluation.
本研究的目的是评估美洛昔康、卡洛芬以及一种含有硫酸软骨素、纯化氨基葡萄糖和抗坏血酸锰（CS-G-M）的慢效疾病修饰性骨关节炎药物对犬甲状腺功能的影响。46只健康（除骨关节炎外）的甲状腺功能正常的犬被随机分为3个治疗组：美洛昔康组、卡洛芬组和CS-G-M组。每组接受推荐剂量的药物治疗60天。另外16只接受安慰剂的骨关节炎甲状腺功能正常的犬作为对照组以验证本研究。对所有组而言，在第0天、第30天和第60天采集血样，以评估血清总甲状腺素和游离甲状腺素以及内源性促甲状腺激素浓度。所有参数在各时间点的治疗组之间或每组在60天期间内均无显著差异。此外，这些值均不在甲状腺功能减退范围内。基于本研究结果，美洛昔康、卡洛芬和CS-G-M的给药不影响犬甲状腺功能评估。
